- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Everolimus Under FDA Scrutiny For Potential Risk
Everolimus has been added to FDA's Adverse Event Reporting System due to a possible risk of hypertension.
Zortress
The US Food and Drug Administration (FDA) has added everolimus (, Novartis) to its FDA Adverse Event Reporting System (FAERS) because of new safety information the agency has received regarding hypertension.
Everolimus is prescribed to treat in patients who have failed previous treatments.
However, the FDA has not released any additional information and "is continuing to evaluate this issue to determine the need for any regulatory action." The signals the agency has received relate to pulmonary hypertension and pulmonary arterial hypertension.
Listing of a drug in FAERS on the FDA's website does not mean the drug should not be prescribed or that patients should stop taking it. The FDA advises discussing any concerns with healthcare providers. The agency will follow up with comment for the public once an investigation is done.
Link to the FDA website: http://1.usa.gov/1vOfw2v
Link to the article on Medscape: http://bit.ly/1woXodD
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
